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Abstract 
Background: Impact of cardiorespiratory fitness on statin-related incidence of type 2 
diabetes has not been assessed. We assessed the cardiorespiratory fitness and 
diabetes incidence association in dyslipidemic patients on statins. 
Methods: We identified dyslipidemic patients with a normal exercise test performed 
during 1986 and 2014 at the Veterans Affairs Medical Centers in Washington, DC or 
Palo Alto, California. The statin-treated patients (n=4,092; age=58.8±10.9 years) 
consisted of 2,701 African-Americans and 1,391 Caucasians. None had evidence of 
type 2 diabetes prior to statin therapy. We formed four fitness categories based on age 
and peak Metabolic Equivalents achieved: Least-fit (n=954); Low-fit (n=1,201); 
Moderate-fit (n=1,242); and High-fit (n=695). The Non-statin treated cohort (n=3,001; 
age=57.2±11.2 years) with no evidence of type 2 diabetes prior to the exercise test 
served as controls. 
Results: Diabetes incidence was 24% higher in statin-treated compared to non-statin 
treated patients (p<0.001). In the statin-treated cohort, 1075 (26.3%) developed 
diabetes (average annual incidence rate of 30.6 events/1,000 person-years). Compared 
to the Least-Fit, adjusted risk declined progressively with increasing fitness and was 
34% lower for High-fit patients (hazard ratio [HR] 0.66; 95% confidence interval [CI] 
0.53-0.82; p<0.001). Compared to the non-statin cohort elevated risk was only evident 
in the Least-Fit (HR 1.50; 95% CI 1.30-1.73; p<0.001) and Low-Fit patients (HR 1.22; 
95% CI 1.06-1.41; p=0.006). 
Conclusions: Risk of diabetes in statin-treated dyslipidemic patients was inversely and 
independently associated to cardiorespiratory fitness. The increased risk was evident 
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only in relatively low fitness patients. Improving fitness may modulate the potential 
diabetogenic effects of statins.  
 
Key Words: cardiorespiratory fitness, statins, type 2 diabetes incidence  
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Introduction 
Statins have become the most widely prescribed medication in the US.1 According to 
the 2013 ACC/AHA Task Force on treatment of cholesterol,2 the number of US adults 
receiving or eligible for statin therapy would increase from 43.2 million (37.5%) currently 
to 56.0 million.1 Observational studies and several meta-analyses of randomized 
controlled trials of statins have reported unfavorable glycemic homeostasis3 and higher 
risk for developing type 2 diabetes in those treated with statins compared to placebo or 
standard care4-6 The risk was found to be dose-related.5 The mechanisms of statin-
induced increase in dysglycemia and risk for type 2 diabetes have not been established. 
Results from a genetic analysis of samples available from 43 randomized statin trials 
showed that increased risk of type 2 diabetes with statins is at least partially explained 
by the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase.7 Body weight gain 
associated with insulin resistance might partly explain the higher risk of type 2 diabetes 
in statin-treated patients.7,8  
Despite the statin-induced increased risk of type 2 diabetes and the increased 
cardiovascular disease risk associated with type 2 diabetes, the benefit of statin 
treatment for prevention of cardiovascular disease and all-cause mortality outweigh the 
risk, even among patients with existing type 2 diabetes9-11 and statin use is not likely to 
decline. For this reason, lifestyle interventions such as optimization of body weight and 
adequate physical activity to improve cardiorespiratory fitness have been proposed as 
ways to counter the risk of type 2 diabetes in statin-treated patients.7  Evidence from 
large epidemiologic studies strongly support an inverse, independent, and graded 
association between cardiorespiratory fitness, major cardiovascular events, all-cause 
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mortality 12,13 and  risk for developing certain chronic illnesses14,15 including  type 2 
diabetes.16-18 We have also shown that both statin therapy and increased 
cardiorespiratory fitness were independently associated with lower mortality risk in 
those treated and not treated with statins.19  Additionally, the combination of statin 
therapy and increased cardiorespiratory fitness was more effective in lowering mortality 
risk than either alone.11,19 However, the impact of increased cardiorespiratory fitness on 
the development of type 2 diabetes in statin-treated patients has not been examined. 
Furthermore, some 20,21 but not all studies 22-24 suggest that improvements in 
cardiorespiratory fitness in response to exercise training may be blunted by statin 
therapy. Therefore, in the current study we sought to assess the impact of 
cardiorespiratory fitness on the incidence of type 2 diabetes in dyslipidemic patients 
treated with statins.   
 
METHODS 
Study Population 
This prospective cohort study included individuals from the Exercise Testing and Health 
Outcomes Study (ETHOS) at the Veterans Affairs Medical Centers, Washington, DC, 
and the Veterans Exercise Testing Study (VETS) at the Veterans Hospital in Palo Alto, 
CA. Both are prospective observational studies designed to address the impact of 
exercise capacity, clinical and lifestyle factors and their association with disease states 
and health outcomes. The cohort consisted of 21,890 individuals who completed a 
symptom-limited exercise tolerance test at two Medical Centers between 1986 and 
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2014, as part of a routine evaluation, clearance to participate in exercise, or assessment 
of suspected coronary artery disease.  
From this cohort, we identified those with documented dyslipidemia treated with 
statins for at least 6 months and no clinical history of type 2 diabetes prior to the 
initiation of statin therapy and no evidence of ischemia during the exercise tolerance 
test. We excluded those with any of the following: 1) exercise capacity <2 Metabolic 
Equivalents; 2) body mass index <18.5 kg/m2; and 3) those with an implanted 
pacemaker, left bundle-branch block, chronic obstructive pulmonary disease, or 
musculoskeletal factors that prevented them from completing the exercise tolerance test 
and those with acquired immune deficiency syndrome or human immunodeficiency 
virus. After these exclusions, the participant group for the current study (n = 4,092) 
consisted of 2,701 African Americans (mean age=58.3 ±10.7 years) and 1,391 
Caucasians and other ethnicities (mean age=59.6±11.1 years). In addition to the statin-
treated cohort we identified 3,001 Veterans (age=57.2±11.2 years) not treated with 
statins who had a normal exercise test and no evidence of type 2 diabetes prior to the 
test to serve as controls. The institutional review board at each institution approved the 
study, and all patients gave written informed consent prior to their exercise tolerance 
test. 
Assessments of Co-variables 
Detailed information on relevant demographic, clinical history, concurrent medications 
and risk factors as defined by International Classification of Diseases-9 for all 
participants was obtained from electronic medical records at the time of the exercise 
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tolerance test. Body weight and height were assessed with a standardized scale and 
recorded prior to exercise tolerance test. Body mass index was calculated as weight in 
kilograms divided by height squared in meters squared.  
Assessments of Exercise Capacity 
Cardiorespiratory fitness was assessed by a standard treadmill test using the Bruce 
protocol at the Veterans Affairs Medical Center in Washington, DC, and an 
individualized ramp protocol as described previously20 for subjects assessed at the 
Veterans Affairs Health Care System Center in Palo Alto, CA. Peak exercise capacity 
(Metabolic Equivalents) was estimated by use of standardized equations.20,21 One 
Metabolic Equivalent is defined as the energy expended at rest, which is approximately 
equivalent to an oxygen consumption of 3.5 mL oxygen per kg body weight per minute. 
Subjects were encouraged to exercise until volitional fatigue in the absence of 
symptoms or other indications for stopping.22 The use of handrails was allowed only if 
necessary for balance and safety and not support. Medications were not altered before 
testing.  
 
Fitness Categories  
We stratified the cohort into four age categories (<50; 50-59; 60-69 and ≥70 years) and 
identified those with an exercise capacity ≤25%; >25% to 50%; >50% to 75% ; and 
>75% of Metabolic Equivalents achieved within their respective age category, as 
described previously.15,19 We then established the following four cardiorespiratory 
fitness categories based on age-stratified quartiles of peak Metabolic Equivalents 
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achieved: Least-fit (4.8±1.2 Metabolic Equivalents; range: 2.0-7.8; n=954); Low-fit 
(6.5±1.1 Metabolic Equivalents; range: 4.5-8.9; n=1,201); Moderate-fit (8.0±1.1 
Metabolic Equivalents; range: 5.5-10.9; n=1,242); and High-fit (10.3±2.1 Metabolic 
Equivalents; range: 7.0-19.0; n=695). The primary endpoint was the development of 
type 2 diabetes determined as of December 31, 2014.  Type 2 diabetes diagnosis was 
based on International Classification of Diseases-9 obtained from each patient 
electronic medical record. Dates of the onset of type 2 diabetes were verified using the 
Computerized Patient Record System available within the Veterans Affairs Health Care 
System.   
Statistical Analysis 
Follow-up time was calculated from the date of statins therapy initiation to the 
date of the event (type 2 diabetes); and to the date of death or December 31, 2014, for 
those who did not develop type 2 diabetes. Follow-up time is presented as median and 
mean ± SD. Event rate was calculated as the ratio of type 2 diabetes by the person-
years of observation. Continuous variables are presented as mean ± SD and 
categorical variables as relative frequencies (%). Baseline associations between 
categorical variables were tested with the χ2 test. Analysis of variance was applied to 
evaluate mean differences of normally distributed variables between statin and non-
statin-treated groups and cardiorespiratory fitness categories.  
A fully adjusted Cox proportional hazards model was constructed to assess the 
risk of type 2 diabetes between the statin-treated and non-statin treated groups. 
Adjusted and unadjusted Cox proportional hazards models were also constructed to 
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compare risks for developing type 2 diabetes across the four cardiorespiratory fitness 
categories within the statin treated group. In these analyses the Least-fit category 
served as the reference group. Finally, we compared the risk of the four statin-treated 
fitness categories to that of the entire non-statin-treated group. For this analysis, the 
entire non-statin-treated group was used as the reference group.  
In all fully adjusted models the covariates were: age in years, peak Metabolic 
Equivalents (when appropriate), body mass index, race, gender, alcohol/drug abuse, 
smoking status, sleep apnea, hypertension, and anti-hypertensive/cardiac medications 
(β-blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme 
inhibitors [ACEI], and angiotensin II receptor blockers [ARB]). All co-variables included 
in the models were based on the rationale of their clinical role on the outcome and the 
main factors of interest. The assumption of proportionality for the Cox proportional 
hazards models was graphically tested by plotting the logarithm of the cumulative 
hazards with time for each covariate; the proportionality assumption was fulfilled for 
each model. All hypotheses were 2 sided, and p-values <0.05 were considered 
statistically significant. All statistical analyses were performed with SPSS software 
version 24.0 (SPSS Inc, Armonk, NY: IBM Corp). 
Results 
The incidence of type 2 diabetes was 24% higher (HR 1.24; 95% CI 1.11-1.39; p<0.001) 
in statin-treated compared to non-statin treated patients. The non-statin cohort was 
younger than the statin-treated cohort (57.2 ±11.1 vs 58.7±10.9 vs years; p<0.001) had 
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similar body mass index and higher cardiorespiratory fitness (7.9 ±2.9 vs 7.2 ±2.3 
Metabolic Equivalents; p<0.001).  
For the 4,092 (179 females) statin-treated patients the follow-up time ranged 
from 0.50 to 27.0 years (mean, 8.3±5.2 years). The median follow-up time was 8.3 
years (4.3 and 12.3 for 25th, and 75th percentiles, respectively), comprising 35,177 
person-years. In this cohort, there were 1,075 type 2 diabetes events (26.3%) with an 
average annual incidence rate of 30.6 events per 1,000 person-years. There were no 
interactions between site and Metabolic Equivalents (p=0.31) or race and Metabolic 
Equivalents (P=0.41); therefore, the data were not stratified by site or race.  
Baseline demographic and clinical characteristics across cardiorespiratory fitness 
categories for the statin-treated group are presented in Table 1. Age was similar across 
all cardiorespiratory fitness categories. However, significant differences were evident 
across cardiorespiratory fitness categories. In general, body weight, body mass index, 
blood pressure, and lipoprotein-lipid profile were more favorable with increased 
cardiorespiratory fitness. Similarly, the prevalence of comorbidities, and the use of anti-
hypertensive/cardiac medications were substantially lower or more favorable for 
individuals with increased cardiorespiratory fitness categories.  
Predictors of Type 2 Diabetes  
Multivariable Cox proportional hazards analysis revealed that body mass index, (HR 
1.07; 95% CI 1.05-1.08; p<0.001), hypertension (HR 1.49; 95% CI 1.21-1.83; p<0.001), 
smoking (HR 1.89; 95% CI 1.66-2.14; p<0.001), sleep apnea (HR 1.35; 95% CI 1.15-
1.59; p<0.001), and exercise capacity were strong predictors of type 2 diabetes 
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incidence. For each 1 Metabolic Equivalent increase in cardiorespiratory fitness, the 
adjusted HR for incidence of type 2 diabetes was 6% lower (HR =0.94; CI 0.91-0.97; 
p<0.001).  
The relative risks for developing type 2 diabetes across cardiorespiratory fitness 
categories are presented in Table 2 and Figure 1. In the fully adjusted model, type 2 
diabetes risk progressively decreased as exercise capacity increased. The risk was not 
altered significantly when treatment with β-blockers and diuretics only (medications 
known to increase the incidence of diabetes) or when ACEIs and ARBs only were 
considered in a separate analyses (findings not included).  
Finally, we performed an additional multivariable Cox proportional hazards 
analysis to further access the impact of cardiorespiratory fitness on the risk of 
developing diabetes.  For this analysis, we used the non-statin treated cohort as the 
reference group and compared it with the aforementioned fitness categories of the 
statin-treated cohort. Diabetes incidence was significantly elevated for individuals in the 
Least-Fit (HR 1.50; 95% CI 1.30-1.73; p<0.001) and Low-Fit (HR 1.22; 95% CI 1.06-
1.41; p=0.006) categories. For the Moderate and High-Fit individuals the risk was similar 
to those not treated with statins.   
 
Discussion 
The findings of the current study support that statins increase the risk for 
developing diabetes in United States veterans to a magnitude within the range reported 
by several studies.6   However, the unique finding of the current study is that the 
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increased risk for diabetes was only evident in individuals with poor cardiorespiratory 
fitness. This concept is supported by two findings. First, when compared to the Least-Fit 
individuals, the adjusted risks for developing type 2 diabetes declined progressively, 
with the risk being 18%; 24% and 34% lower for Low-Fit, Moderate-fit and High-fit 
individuals, respectively. Second, when compared to those not treated with statins, the 
higher risk for developing diabetes was only evident for those in the two lowest fitness 
categories (Least-Fit and Low-Fit). Specifically, the risk of incidental type 2 diabetes 
was 50% higher in Least-fit individuals treated with statins and 22% higher in the Low-fit 
individuals. The risk was virtually eliminated for the Moderate-fit and High-fit individuals 
(Figure 2). This suggests that the potential increased risk for developing type 2 diabetes 
associated with statin therapy may be modulated by increased cardiorespiratory fitness.  
When considering the worldwide rise in type 2 diabetes incidence related, at 
least in part to the obesity epidemic and low physical activity and cardiorespiratory 
fitness as well as the pervasive use of statins worldwide, even a relatively minor 
tendency for statins to increase type 2 diabetes incidence can have significant 
implications on global health. Moreover, statins not only promote diabetogenesis, but 
also have a detrimental impact on glycemic control in established type 2 diabetes and 
type 1 diabetes mellitus patients, greatly increasing their pathophysiological influence.25 
In this regard, the findings of the current study support that adequate levels of physical 
activity to increase cardiorespiratory fitness provides a means to counteract the 
diabetogenic propensities of statin therapy. The cardiorespiratory fitness level 
necessary to lower the risk of type 2 diabetes significantly within the statin-treated group 
was approximately 8 Metabolic Equivalents (Table 2).  Furthermore, at this fitness level, 
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the higher incidence of diabetes observed in the Least and Low-fit patients when 
compared to the non-statin-treated group, was virtually eliminated (Figure 2).  This 
cardiorespiratory fitness level is achievable by most middle-aged and older individuals 
by moderate levels of physical activity such as 30-40 minutes of brisk walk most days of 
week.26,27 It is also well within the cardiorespiratory fitness level shown to work 
synergistically with statin therapy and most effectively lower mortality risk in 
dyslipidemic patients.19 The interaction between cardiorespiratory fitness, type 2 
diabetes, and statin use provides an additional impetus for health care providers to 
promote moderate physical activity in order to reduce the burden of type 2 diabetes.26-28   
This study has several strengths and limitations inherent in prospective follow-up 
studies. Importantly, cardiorespiratory fitness levels were based on only 1 assessment, 
and follow-up data on cardiorespiratory fitness status of the participants was not 
available. The use of 2 different exercise protocols to assess cardiorespiratory fitness is 
also a potential limitation. Previous work suggests that the ramp protocol is somewhat 
more accurate in predicting estimated Metabolic Equivalents.29,30  However, separate 
analyses from the 2 locations yielded similar results, suggesting that the differences in 
protocols had minimal impact.29,31,32  We did not have an adequate number of 
participants to assess risk in those <30 years of age. Dietary information was also not 
available in our records. Finally, mostly male veterans were included, which limits the 
ability to generalize the findings to women and other non-veteran populations.  
There are also certain attributes that make our findings unique and applicable to 
other populations. This was a comparatively large study to address the association 
between cardiorespiratory fitness status assessed objectively and incidence of type 2 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Kokkinos P., et al.   AJM 3-30-2017 
14 
 
diabetes in a clinically-referred cohort (n=7,093) with a follow-up of 81,768 person-
years. Our cohort has equal access to care independent of a patient’s financial status 
provided by the Veterans Health Administration. This permits epidemiologic evaluations 
while minimizing the influence of disparities in medical care.33-35 In addition, the 
existence of electronic health records within the Veterans Affairs Healthcare System 
enables accurate identification of the onset of type 2 diabetes and the initiation or 
discontinuation of statin therapy, as well as detailed observation of prior history, 
medications, co-morbidities and alterations in health status. These attributes, allowed 
greater accuracy in defining our cohort, minimize the likelihood of reverse causality and 
support the validity of the cardiorespiratory fitness - type 2 diabetes risk association 
across the age spectrum. However, the current findings are based on epidemiologic 
data, derived form a cohort of veterans and should be interpreted with caution. Future 
studies are needed to validate and expand our findings to different populations. 
Conclusions 
The current of the current study suggest that the risk of type 2 diabetes incidence in 
dyslipidemic patients treated with statins may be significantly attenuated by moderate 
increases in cardiorespiratory fitness. Therapeutic interventions including increasing 
physical activity through rehabilitation or community exercise programs to improve 
cardiorespiratory fitness should be encouraged in high-risk individuals, especially those 
on statins. These results provide further support for health care professionals and health 
organizations to promote physical activity in order to reduce the public health care 
burden of type 2 diabetes and support the promotion of physical activity throughout the 
healthcare system and throughout the globe.27,36,37  
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Table 1. Demographic and clinical characteristics according to fitness categories 
 
Least-fit Low-fit Moderate-fit High-fit p-value 
n (%) 954 1,201 1,242 695  
Age (yrs) 58.2±10.9 58.8±11.0 58.8±10.7 59.5±10.9 0.121 
Weight (Kg) 94.0±20.2 92.2±17.6 89.3±15.1 85.5±13.7 <0.001 
Body Mass Index (kg/m2 ) 30.3±6.1 29.7±5.0 28.8±4.3 27.6±4.0 <0.001 
Resting Heart Rate 
(beats/min) 
73.7±14.0 71.6±13.1 68.4±11.8 67.3±12.4 <0.001 
Rest Systolic Blood 
Pressure (mm Hg) 
131.9±20.9 129.8±19.6 126.7±18.0 127.0±17.9 <0.001 
Rest Diastolic Blood 
Pressure (mm Hg) 
80.3±12.3 78.8±11.5 78.0±10.8 78.1±10.9 <0.001 
Peak MET 4.8±1.2 6.5±1.1 8.0±1.1 10.3±2.1 <0.001 
Total Cholesterol (mg/dL) 190.6±44.1 195.9±47.2 194.2±46.0 193.9±40.8 0.701 
Triglycerides (mg/dL) 141.8±82.5 136.6±91.8 122.7±88.3 113.7±68.5 0.025 
Low Density Liporoptein -
Cholesterol (mg/dL) 
118.5±36.8 126.0±86.2 123.7±41.4 129.4±40.7 0.081 
High Density Lipoprotein -
Cholesterol (mg/dL) 
42.1±12.0 43.8±12.7 45.3±13.0 45.2±12.4 0.034 
Glucose (mg/dL) 105.5±33.5 101.4±24.6 98.9±21.0 95.0±14.7 <0.001 
Type 2 Diabetes Incidence 
(%) 
444 (30.9) 449 (25.9) 288 (23.2) 123 (17.7) <0.001 
Hypertension (%) 824 (25.7) 984 (30.6) 957 (29.8) 447 (13.9) <0.001 
Smoking (%) 408 (30.8) 448 (33.8) 326 (24.6) 144 (10.9) <0.001 
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Sleep Apnea (%) 113 (22.6) 168 (33.7) 171 (34.3) 47 (9.4) <0.001 
Antihypertensive/Cardiac 
agents (%) 
879 (25.0) 1,089 (30.9) 1,058 (30.0) 496 (14.1) <0.001 
ACEI/ARBS (%) 71 (22.0) 116 (36.0) 99 (30.7) 36 (11.2) 0.006 
β-blockers/diuretics (%) 243 (23.4) 295 (28.4) 330 (31.8) 169 (24.3) 0.621 
Drug/Alcohol abuse (%) 108 (28.3) 130 (34.0) 105 (27.5) 39 (10.2) 0.001 
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Table 2. Risk for developing type 2 diabetes according to fitness categories 
 
Patients (n) 
Type 2 Diabetes  
(n; %) 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)* 
p value† 
Least-Fit (Referent; 4.8±1.2 
Metabolic Equivalents) 
954 395  
(41.4%) 
1 1 - 
Low-Fit (6.5±1.1 Metabolic 
Equivalents) 
1,201 420 
(35.0%) 
0.75 
(0.64-0.87) 
0.82 
(0.70-0.95) 
0.009 
Moderate-Fit (8.0±1.1 
Metabolic Equivalents) 
1,242 378 
(30.4%) 
0.59  
(0.50-0.69) 
0.76  
(0.65-0.90) 
0.001 
High-Fit (10.3±2.1 Metabolic 
Equivalents) 
695 145 
(20.9%) 
0.41 
(0.34-0.51) 
0.66 
(0.53-0.82) 
<0.001 
HR=hazard ratio 
* Adjusted for age, body-mass index, race, gender, β blockers, calcium channel blockers, diuretics, angiotensin-
converting enzymes, angiotensin II receptor blockers, smoking, hypertension, sleep apnea, and alcohol/drug abuse  
†For fully adjusted HR 
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Follow-up (years)
Figure 1. Relative risk for developing type 2 diabetes according to cardiorespiratory fitness categories
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Figure 2  Risk for developing type 2 diabetes according to fitness status in statin-treated patients with 
dyslipidemia compared to the non-statin treated group. Fitness categories  represent  individuals in the 
statin-treated group only. Numbers in parentheses denoting peak Metabolic Equivalents achieved.  
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Clinical Significance 
• Recent studies have shown an increase in the incidence of type 2 diabetes with 
statin therapy 
• Since the use of statins is considerably high, ways to attenuate the incidence of 
Type 2 diabetes is clinically important 
• Cardiorespiratory fitness improves metabolic parameters and attenuates the risk 
for developing Type 2 diabetes  
• The findings of the current study support that cardiorespiratory fitness modulates 
the statin-associated risk for developing type 2 diabetes 
 
 
